洛莫司汀
医学
贝伐单抗
危险系数
内科学
临床终点
无进展生存期
置信区间
随机化
外科
联合疗法
肿瘤科
随机对照试验
化疗
长春新碱
环磷酰胺
作者
Wolfgang Wick,Thierry Gorlia,Martin Bendszus,Martin Taphoorn,Felix Sahm,Inga Harting,Alba A. Brandes,Walter Taal,Julien Dômont,Ahmed Idbaïh,Mario Campone,Paul M. Clément,Roger Stupp,Michel Fabbro,Émilie Le Rhun,François Dubois,Michael Weller,Andreas von Deimling,Vassilis Golfinopoulos,Jacoline C. Bromberg
标识
DOI：10.1056/nejmoa1707358
摘要
Despite somewhat prolonged progression-free survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with lomustine alone in patients with progressive glioblastoma. (Funded by an unrestricted educational grant from F. Hoffmann-La Roche and by the EORTC Cancer Research Fund; EORTC 26101 ClinicalTrials.gov number, NCT01290939 ; Eudra-CT number, 2010-023218-30 .).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
Kao
cdercder
Nole
GingerF
LB
Criminology34
OK
Samuel
sci_fp
MchemG
Albert_Z
wueeee
斯文的初蝶
kakao
arniu2008
披着羊皮的狼
Copyright
做实验的猫
右子
YifanWang
皖公网安备34019202002308
